LGD-4033
LGD-4033. Tissue-selective androgen receptor partial agonist — high anabolic activity in muscle + bone with reduced androgenic effects in prostate, skin, liver. AR…
Tissue-selective androgen receptor partial agonist — high anabolic activity in muscle + bone with reduced androgenic effects in prostate, skin, liver. AR selectivity ratio ~10:1 vs testosterone's 1:1. Phase 1 studies (Viking Therapeutics) showed muscle mass + strength gains over 21 days.
PK: STRIPPED. MY PRIOR THAT A HUMAN PHASE-1 EXISTS WAS RIGHT AND IT IS CORRECTLY CITED — seventy-six men, three ascending doses, twenty-one days — BUT ITS ABSTRACT STATES ONLY "LGD-4033 had a long elimination half-life and dose-proportional accumulation upon multiple dosing", WITH NO NUMBER ANYWHERE, so the stored half-life came from full text or a secondary source. All twenty-five indexed hits were swept: doping-control metabolite identification, urinary detection windows, one EQUINE administration study, one rat model and a self-administration case report — NOT ONE ABSOLUTE PARAMETER FOR THE PARENT. IT DIFFERS FROM THE OTHER RESEARCH COMPOUNDS IN THAT HUMAN DATA GENUINELY EXIST, and is still unauthorable under the verbatim rule. A SEPARATE DOSE DEFECT GOES WITH IT: the stored range is ILLICIT dosing, five to ten times the highest dose ever given to a human in a study, paired with a half-life no abstract states.
Sources: PMID:22459616